National Defence Minister Bill Blair, speaking from Parliament Hill on Monday following the Canada-U.S. relations council ...

AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based ...

Nebraska lawmakers gave resounding first-round approval Monday to Gov. Jim Pillen's proposed law that would require every ...

Canada continues arms exports to Israel unimpeded, exploiting loopholes that allow military goods to flow through the U.S., “unreported and unregulated,” organizer Gur Tsabar, a spokesperson of the ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

The debate around taxation of cruise operators has been around for years. What would the impact be on the cruise lines?

Halfway through the session, legislative priorities are emerging. But the new uncertainties mean lawmakers may need a special ...

Equities researchers at William Blair increased their FY2026 EPS estimates for argenx in a research note issued on Friday, ...

Investment analysts at William Blair boosted their Q3 2026 earnings per share (EPS) estimates for shares of Salesforce in a ...

William Blair issued their Q1 2026 EPS estimates for Cullinan Therapeutics in a report issued on Thursday, February 27th. William Blair analyst M. Phipps expects that the company will post earnings of ...

William Blair issued their Q1 2026 earnings estimates for shares of Verve Therapeutics in a report issued on Thursday, ...

Analysts at William Blair issued their Q1 2026 earnings estimates for shares of Rocket Pharmaceuticals in a note issued to ...